Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effectiveness and safety of the treatment of lysosomal deposit diseases: Analysi...
Journal Information
Vol. 159. Issue 8.
Pages 380-384 (October 2022)
Share
Share
Download PDF
More article options
ePub
Visits
3
Vol. 159. Issue 8.
Pages 380-384 (October 2022)
Brief report
Effectiveness and safety of the treatment of lysosomal deposit diseases: Analysis of 22 patients
Efectividad y seguridad del tratamiento de las enfermedades de depósito lisosomal: análisis de 22 pacientes
Visits
3
Dolores Canales-Sigueroa,
Corresponding author
mcanales@salud.madrid.org

Corresponding author.
, Carmen García-Muñoza, Pilar Quijada Fraileb, Montserrat Morales Conejoc, José Miguel Ferrari-Piqueroa, Elena Martín-Hernándezb
a Servicio de Farmacia, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
b Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Servicio de Pediatría, Centro de Referencia Nacional para Enfermedades Metabólicas Hereditarias, Hospital Universitario 12 de Octubre, Madrid, Spain
c Servicio de Medicina Interna, Consulta de Enfermedades Minoritarias, CSUR de Errores Congénitos del Metabolismo, Hospital Universitario 12 de Octubre, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Objectives

Identify the efficacy variables collected in the literature for therapies used in lysosomal storage diseases (LDS), evaluate the quality of this evidence, and know the effectiveness and safety of these treatments.

Material and methods

Retrospective observational study that included patients with LDS treated with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). Published clinical trials (CT) and LDS treatment guidelines were reviewed to select efficacy variables. Data to measure them (and adverse effects) were obtained from the medical history.

Results

No CTs have been found in which efficacy is evaluated with final variables, all have been surrogated. Twenty-two patients were included: eight with Gaucher disease, six with Niemann-PickC disease, two with Hunter disease, one with Morquio-A disease, and five with Pompe disease. Eight patients have responded to ERT and one to SRT with eliglustat. ERT hasn't been associated with adverse effects. Miglustat has produced tolerance problems, requiring a change in a patient.

Conclusions

The effectiveness was variable according to the pathology. Regarding safety, manageable adverse reactions to SRT were associated with dosage adjustments.

Keywords:
Effectiveness
Security
Weird illness
Treatment
Lysosomal storage disease
Resumen
Objetivos

Los objetivos son: identificar variables de eficacia empleadas en fármacos para enfermedades de depósito lisosomal (EDL), evaluar la calidad de esta evidencia, y conocer la efectividad y seguridad de estos tratamientos.

Material y metodos

Estudio observacional retrospectivo que incluyó pacientes con EDL tratados con terapia de sustitución enzimática (TSE) o de reducción de sustrato (TRS). Se revisaron los ensayos clínicos (EC) publicados y guías de tratamiento de EDL para seleccionar variables de eficacia. Se obtuvieron los datos para medirlas (y efectos adversos) de la historia clínica.

Resultados

No se encontraron EC en los que se evalúe eficacia con variables finales, todas fueron subrogadas. Se incluyeron 22 pacientes: ocho con enfermedad de Gaucher, seis con enfermedad de Niemann-PickC, dos con enfermedad de Hunter, uno con enfermedad de Morquio-A y cinco con enfermedad de Pompe. Ocho pacientes respondieron a TSE y uno a TRS. La TSE no se relacionó con efectos adversos. Miglustat produjo problemas de tolerancia que requirieron cambio de tratamiento en un paciente.

Conclusiones

La efectividad fue variable según la patología. Respecto a seguridad, se asociaron reacciones adversas a TRS manejables con ajustes posológicos.

Palabras clave:
Efectividad
Seguridad
Enfermedad rara
Tratamiento
Enfermedad de depósito lisosomal

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos